Structure via PubChem · Public domain (PubChem)
indacaterol
Sign in to saveAlso known as QAB149, QAB-149, QAB 149, 5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered through a dry powder inhaler.
In the Vinony graph
Within Vinony's link graph, indacaterol is referenced by 633 other articles, and connects out to propranolol, atenolol and adrenergic receptor.
It sits within the topics 2-Aminoindanes, 2-Quinolones and Drugboxes which contain changes to verified fields.
Its subject is documented across 20 Wikipedia language editions.
Chemical data
- Formula
- C24H28N2O3
- Molecular weight
- 392.5 g/mol
- IUPAC name
- 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
- SMILES
- CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
- InChIKey
- QZZUEBNBZAPZLX-QFIPXVFZSA-N
- XLogP
- 3.3
- Polar surface area
- 81.6 Ų
- H-bond donors
- 4
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2009
- Admin. routes
- topical
- Indications
- Airway obstruction, chronic obstructive pulmonary disease, heart failure, asthma
via ChEMBL · EBI
Research
630 papers- Indacaterol.2006
- Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.The New England journal of medicine · 2016
- Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.Drugs · 2021
- Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma.Expert review of respiratory medicine · 2022
- Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.American journal of respiratory and critical care medicine · 2018
via PubMed
Wikidata facts
- Mass
- 392.209993
- Has use
- medication
Show 9 more facts
- chemical formula
- C₂₄H₂₈N₂O₃
- Commons category
- Indacaterol
- canonical SMILES
- CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
- isomeric SMILES
- CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
- World Health Organisation international non-proprietary name
- indacaterol
- defined daily dose
- 0.15
- medical condition treated
- chronic obstructive pulmonary disease
- physically interacts with
- adrenoceptor beta 2
- significant drug interaction
- sotalol
Sources (7)
via Wikidata · CC0
~1 min read
Encyclopedic overview
3 sectionsContents
- Medical uses
- History
- References
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered through a dry powder inhaler.
==Medical uses== A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists. {| class="wikitable floatright" |+Receptor binding affinities (Ki) [nM] !Receptor !Ki |- |β1 |6.21 |- |β2 |7.36 |- |β3 |5.48 |}
Excerpted from Wikipedia’s “indacaterol” article, available under the CC BY-SA 4.0 licence.